Marqeta Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marqeta Inc trades at $15.52 (market cap $1.62B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Marqeta Inc and Recursion Pharmaceuticals Inc are close in size by market cap. Which is the better fit depends on your goals.
| MQ | RXRX | |
|---|---|---|
Market Cap | $1.62B | $1.81B |
Sector | Technology | Health |
52-Week High | $26.00 | $6.79 |
52-Week Low | $15.04 | $2.84 |
Enterprise Value | $935.36M | $1.33B |
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $15.6, down 2.26% on the day, with a bearish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split and shows improving revenue trends, though profitability remains thin. Recent news highlights partnerships with Google and Riskified to expand product offerings and reduce fraud.
The outlook is cautiously optimistic due to revenue growth and strategic expansions, but high valuation ratios and inconsistent earnings pose risks. Analyst consensus is a Buy with a $19 price target, suggesting potential upside if execution improves and margins expand.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →